Phaseline

Targets › IL5RA

IL5RA (Interleukin-5 receptor subunit alpha): drug programs, companies and trials

4 programs from 4 companies in 18 trials: 9 Phase 3, 5 Phase 2, 3 Phase 4, 1 Phase 1; Respiratory, Immunology, Hematology; next expected readout Nov 2026.

Cell surface receptor that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Acts by forming a heterodimeric receptor with CSF2RB subunit and subsequently binding to interleukin-5. (UniProt, Q01344)

Open in Phaseline: the race on IL5RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaBenralizumab
Interleukin-5 receptor subunit alpha inhibitor
IL5RAPhase 4Asthma; Eosinophilic Asthma; Eosinophilic Granulomatous Vasculitis; Hypereosinophilic Syndrome …Nov 2026
SanofiLunsekimig (SAR443765)
IL-5 receptor alpha antagonist
IL5RAPhase 3Chronic Obstructive Pulmonary Disease; Asthma; Chronic Rhinosinusitis With Nasal PolypsJun 2027
Guangdong Hengrui PharmaceuticalSHR-1703 Injection
IL-5 receptor alpha antagonist
IL5RAPhase 3Asthma With Eosinophilic Phenotype; Eosinophilic Asthma Patients; Eosinophilic Granulomatosis With PolyangiitisSep 2027
Zhejiang UniversityIL-5 CAR-T cells
CAR-T cells targeting IL-5 receptor alpha (CD125)
IL5RAPhase 1Hematologic DiseasesNov 2028

Conditions

Asthma (5) Chronic Obstructive Pulmonary Disease (2) Eosinophilic Asthma (1) Eosinophilic Granulomatous Vasculitis (1) Hypereosinophilic Syndrome (1) Eosinophilic Granulomatosis With Polyangiitis (EGPA) (1) Asthma; Eosinophilic (1) Moderate to Severe Asthma (1) Chronic Rhinosinusitis With Nasal Polyps (1) Asthma With Eosinophilic Phenotype (1) Eosinophilic Asthma Patients (1) Eosinophilic Granulomatosis With Polyangiitis (1)

Modalities

antibody (1), mixed (1), small molecule (1), other (1)

Companies

AstraZeneca (1) Sanofi (1) Guangdong Hengrui Pharmaceutical (1) Zhejiang University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.